Results 1 to 10 of about 123 (103)

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety

Pharmacology Research and Perspectives
Pitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths during clinical trials, has propelled it into the spotlight of ...
Cheng Jiang
exaly   +2 more sources

Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects

Medicines (Basel, Switzerland), 2020
Background: Besides its well-known role as a peripheral chemical mediator of immune, vascular, and cellular responses, histamine plays major roles in the central nervous system, particularly in the mediation of arousal and cognition-enhancement.
Pius S Fasinu, Fasinu Pius S
exaly   +3 more sources

Pitolisant-associated mania – a case report

BMC Neurology
Background Narcolepsy is a chronic neurological disorder treated with medications that promote wakefulness. Pitolisant, a histamine H3 receptor inverse agonist, is used to reduce excessive daytime sleepiness.
Maximilian Zoltek, Richard Ågren
doaj   +3 more sources

Update on the treatment of narcolepsy: clinical efficacy of pitolisant

Nature and Science of Sleep, 2017
Michael W Calik1,2 1Department of Biobehavioral Health Science, 2Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, IL, United States Abstract: Narcolepsy is a neurological disease that affects 1 in 2,000 ...
Calik MW
doaj   +6 more sources

Pitolisant nanofibers: A promising frontier in drug delivery for narcolepsy - Formulation, optimisation, and characterization insights

Biomedical Technology
The study focuses on developing a new way to deliver the narcolepsy medication pitolisant. Electrospinning was used to make polyvinyl alcohol (PVA) and hyperbranched polyglycerol (HPG) polymers into pitolisant nanofibers (PT-NF).
J Nandhini, Karthikeyan Elumalai, S Rajeshkumar   +2 more
exaly   +3 more sources

Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review [PDF]

Cureus, 2021
Narcolepsy is characterized by excessive daytime sleepiness (EDS) and cataplexy. Histamine neurons play an important role in enhancing wakefulness. The objective of our study was to evaluate the efficacy of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist, in patients with a high burden of narcolepsy symptoms. We conducted an advanced
Fabara, Stephanie P, Ortiz, Juan Fernando, Anas Sohail, Anas, Hidalgo, Jessica, Altamimi, Abbas, Tama, Belen, Patel, Urvish K   +6 more
openaire   +2 more sources

Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority metaanalytical approach

Drugs in Context, 2020
Aim: To assess the non-inferiority of pitolisant, a new compound for the relief of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy, compared with modafinil.
Philippe Lehert, Cassandra Szoeke
doaj   +1 more source

The impact of pitolisant, an H3 receptor antagonist/inverse agonist, on perirhinal cortex activity in individual neuron and neuronal population levels

Scientific Reports, 2022
Histamine is a neurotransmitter that modulates neuronal activity and regulates various brain functions. Histamine H3 receptor (H3R) antagonists/inverse agonists enhance its release in most brain regions, including the cerebral cortex, which improves ...
Kyosuke Hirano, Yoshikazu Morishita, Masabumi Minami, Hiroshi Nomura   +3 more
doaj   +1 more source

Dual Targeting Ligands—Histamine H₃ Receptor Ligands with Monoamine Oxidase B Inhibitory Activity—In Vitro and In Vivo Evaluation

Pharmaceutics, 2022
The clinical symptoms of Parkinson’s disease (PD) appear when dopamine (DA) concentrations in the striatum drops to around 20%. Simultaneous inhibitory effects on histamine H3 receptor (H3R) and MAO B can increase DA levels in the brain.
Dorota Łażewska, Agata Siwek, Agnieszka Olejarz-Maciej, Agata Doroz-Płonka, Anna Wiktorowska-Owczarek, Marta Jóźwiak-Bębenista, David Reiner-Link, Annika Frank, Wioletta Sromek-Trzaskowska, Ewelina Honkisz-Orzechowska, Ewelina Królicka, Holger Stark, Marek Wieczorek, Waldemar Wagner, Katarzyna Kieć-Kononowicz, Anna Stasiak   +15 more
doaj   +1 more source

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol

Pharmacology Research & Perspectives, 2021
Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea.
Stéphane Krief, Isabelle Berrebi‐Bertrand, Isabelle Nagmar, Martin Giret, Simon Belliard, David Perrin, Marilyne Uguen, Philippe Robert, Jeanne‐Marie Lecomte, Jean‐Charles Schwartz, Olivier Finance, Xavier Ligneau   +11 more
doaj   +1 more source